2023-05-29
On May 29, 2023, Shenzhen Beimei Pharmaceutical Co., LTD. (hereinafter referred to as "Beimei Pharmaceutical") has officially received the acceptance letter issued by the Drug Evaluation Center of the National Medical Products Administration. The procaterol hydrochloride oral solution, which isindependently developed by Beimei Pharmaceutical,its application was accep...
More +2023-03-22
A few days ago, Shenzhen Small and medium-sized Enterprise Service Bureau released the "Shenzhen Small and Medium-sized Enterprise Service Bureau- the list of Shenzhen SRDI small and medium-sized enterprises in 2022", after enterprise declaration, expert review and other aspects, with the outstanding performance of children medicine field, Shenzhen Beimei Pharmaceutic...
2023-03-22
A few days ago, Shenzhen Small and medium-sized Enterprise Service Bureau released the "Shenzhen Small and Medium-sized Enterprise Service Bureau- the list of Shenzhen SRDI small and medium-sized enterprises in 2022", after enterprise declaration, expert review and other aspects, with the outstanding performance of children medicine field, Shenzhen Beimei Pharmaceutic...
2023-03-09
February 28, 2023, Three doses (10 mg, 20 mg, 40 mg) ofEsomeprazole magnesium for delayed release oral suspension（卫艾宁®）, the imported finished product which islicensed fromCipla Ltd. , were formally approved by the NMPA, the National Medical Products Administration. It is approved for the treatment of gastroesophageal reflux disease, eradication of Helicobacter pylori in combi...
2023-03-09
February 28, 2023, Three doses (10 mg, 20 mg, 40 mg) ofEsomeprazole magnesium for delayed release oral suspension（卫艾宁®）, the imported finished product which islicensed fromCipla Ltd. , were formally approved by the NMPA, the National Medical Products Administration. It is approved for the treatment of gastroesophageal reflux disease, eradication of Helicobacter pylori in combi...
2023-02-10
On February 03, 2023, Shenzhen BeimeiPharmaceutical Co., Ltd (hereinafter referred to as "BeimeiPharmaceutical") received the Acceptance Notice issued by the State Drug Administration of China (SDA), and the application for marketing authorization for the production of DesloratadineOral Solution within the Company's territory was accepted.DesloratadineOral So...
2023-02-10
On February 03, 2023, Shenzhen BeimeiPharmaceutical Co., Ltd (hereinafter referred to as "BeimeiPharmaceutical") received the Acceptance Notice issued by the State Drug Administration of China (SDA), and the application for marketing authorization for the production of DesloratadineOral Solution within the Company's territory was accepted.DesloratadineOral So...
2022-12-26
On December 26, 2022, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") and Syrimed reached an exclusive license and supply agreement of a skeletal muscle relaxation oral solution product (hereinafter referred to as "the product"). Under the terms of the agreement, Beimei will be responsible for the registration and commer...
2022-12-26
On December 26, 2022, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") and Syrimed reached an exclusive license and supply agreement of a skeletal muscle relaxation oral solution product (hereinafter referred to as "the product"). Under the terms of the agreement, Beimei will be responsible for the registration and commer...
2022-12-02
On December 2, 2022, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") and Cipla Ltd. (hereinafter referred to as " Cipla ") reached an exclusive license and supply agreement of a neonatal pharmaceutical product (hereinafter referred to as "the product"). Under the terms of the agreement, Beimei will be respons...
2022-12-02
On December 2, 2022, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") and Cipla Ltd. (hereinafter referred to as " Cipla ") reached an exclusive license and supply agreement of a neonatal pharmaceutical product (hereinafter referred to as "the product"). Under the terms of the agreement, Beimei will be respons...
2022-11-24
Shenzhen Beimei Pharmaceutical Co., Ltd. has successfully obtained the medicine production license B certificate of desloratadine oral solution.Desloratadine oral solution is one more product independently developed by Beimei R & D Center since its establishment. In June 2022, Desloratadine oral solution successfully completed pilot scale-up and process validation production in H...
2022-11-24
Shenzhen Beimei Pharmaceutical Co., Ltd. has successfully obtained the medicine production license B certificate of desloratadine oral solution.Desloratadine oral solution is one more product independently developed by Beimei R & D Center since its establishment. In June 2022, Desloratadine oral solution successfully completed pilot scale-up and process validation production in H...
2022-07-14
Recently, Beimei pharmaceutical co., Ltd (hereinafter referred to as the “Beimei”) and Aosaikang Pharmaceutical Co., Ltd (hereinafter referred to as the “Aosaikang”) have made a cooperative promotion authorization agreement on Esomeprazole magnesium delayed release oral suspension (hereinafter referred to as the "Product") in the specified regions and provinces across the ...
2022-07-14
Recently, Beimei pharmaceutical co., Ltd (hereinafter referred to as the “Beimei”) and Aosaikang Pharmaceutical Co., Ltd (hereinafter referred to as the “Aosaikang”) have made a cooperative promotion authorization agreement on Esomeprazole magnesium delayed release oral suspension (hereinafter referred to as the "Product") in the specified regions and provinces across the ...
2022-07-06
Recently, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as Beimei Pharm) and Jiangsu Aosaikang Pharmaceutical Co., Ltd. (hereinafter referred to as ASK Pharm) announced the strategic cooperation. Both parties will integrate the superior resources to jointly promote innovation and research and development of pediatric prescription drugs and solve unmet clinical needs in China, with a view to initiating in-depth cooperation in R&D transformation, manufacturing, sales promotion and equity cooperation.
2022-07-06
Recently, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as Beimei Pharm) and Jiangsu Aosaikang Pharmaceutical Co., Ltd. (hereinafter referred to as ASK Pharm) announced the strategic cooperation. Both parties will integrate the superior resources to jointly promote innovation and research and development of pediatric prescription drugs and solve unmet clinical needs in China, with a view to initiating in-depth cooperation in R&D transformation, manufacturing, sales promotion and equity cooperation.
2022-07-05
On June 23, 2022, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") and Italy NTC S.r.l. (hereinafter referred to as "NTC") entered into an exclusive License and Supply Agreement for the collaboration of three EU approved Class II medical device (hereinafter referred to as "Products") in China Mainland. Beimei acquire exclusive right to register and commercialize the Products in China Mainland. The Products are oral care products, suitable for children’s use, in two different dosage forms- spray and gel as topical treatment of the oral mucosa suffering from recurrent canker sores.
2022-07-05
On June 23, 2022, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") and Italy NTC S.r.l. (hereinafter referred to as "NTC") entered into an exclusive License and Supply Agreement for the collaboration of three EU approved Class II medical device (hereinafter referred to as "Products") in China Mainland. Beimei acquire exclusive right to register and commercialize the Products in China Mainland. The Products are oral care products, suitable for children’s use, in two different dosage forms- spray and gel as topical treatment of the oral mucosa suffering from recurrent canker sores.
